This human clinical study published in Nutrients characterizes the pharmacokinetics and endocrine effects of orally administered D-Pinitol, both as a purified compound and as part of a natural carob pod–derived syrup (Innosweet®). The research demonstrates that D-Pinitol is efficiently absorbed via the oral route, exhibiting a prolonged absorption phase and an extended half-life exceeding five hours.
When delivered through Innosweet®, D-Pinitol maintains systemic bioavailability while exhibiting a moderate absorption profile, resulting in more controlled plasma exposure. Importantly, D-Pinitol administration reduced insulin secretion without altering blood glucose levels, while increasing glucagon and ghrelin concentrations, supporting a balanced endocrine response rather than a glycemic spike.
These findings highlight Innosweet® as a functional sweetener matrix, capable of delivering sweetness together with metabolic protection. The study positions Innosweet® as a differentiated natural syrup that supports insulin-sparing mechanisms, endocrine pancreas protection, and metabolic resilience, making it relevant for weight management, metabolic health, and functional nutrition applications.